Kerala Ayurveda Ltd
Incorporated in 1945, Kerala Ayurveda Ltd is engaged In Ayurvedlc services and products[1]
- Market Cap ₹ 507 Cr.
- Current Price ₹ 422
- High / Low ₹ 487 / 250
- Stock P/E
- Book Value ₹ 20.9
- Dividend Yield 0.00 %
- ROCE -10.3 %
- ROE -40.8 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 20.2 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 6.25% over past five years.
- Company has a low return on equity of -18.1% over last 3 years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 90.1 to 116 days.
- Working capital days have increased from 105 days to 186 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
26 | 28 | 33 | 40 | 44 | 46 | 54 | 43 | 56 | 63 | 73 | 73 | |
23 | 25 | 28 | 35 | 38 | 43 | 51 | 43 | 48 | 58 | 68 | 85 | |
Operating Profit | 3 | 3 | 4 | 5 | 6 | 3 | 3 | 0 | 8 | 5 | 5 | -13 |
OPM % | 11% | 12% | 12% | 12% | 13% | 6% | 6% | 0% | 14% | 8% | 7% | -17% |
0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 0 | 5 | |
Interest | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 6 | 6 | 5 | 4 | 4 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 |
Profit before tax | 1 | 2 | 2 | 3 | 3 | 2 | 1 | -7 | 1 | 2 | 0 | -13 |
Tax % | 31% | 30% | 31% | 32% | 32% | 31% | 28% | -25% | 28% | -22% | 163% | 2% |
1 | 1 | 2 | 2 | 2 | 1 | 1 | -5 | 1 | 3 | -0 | -14 | |
EPS in Rs | 0.98 | 1.05 | 1.64 | 2.08 | 2.18 | 1.14 | 0.83 | -4.69 | 0.84 | 2.74 | -0.22 | -11.45 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 6% |
3 Years: | 9% |
TTM: | 0% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -5004% |
Stock Price CAGR | |
---|---|
10 Years: | 28% |
5 Years: | 52% |
3 Years: | 79% |
1 Year: | 43% |
Return on Equity | |
---|---|
10 Years: | -6% |
5 Years: | -18% |
3 Years: | -18% |
Last Year: | -41% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 12 | 12 |
Reserves | 3 | 3 | 5 | 4 | 7 | 3 | 4 | -1 | 1 | 4 | 30 | 13 |
60 | 64 | 64 | 52 | 70 | 56 | 58 | 66 | 61 | 64 | 62 | 56 | |
5 | 5 | 5 | 9 | 13 | 17 | 21 | 20 | 19 | 21 | 20 | 38 | |
Total Liabilities | 79 | 84 | 84 | 76 | 100 | 87 | 94 | 96 | 92 | 99 | 124 | 119 |
18 | 17 | 16 | 16 | 16 | 17 | 17 | 26 | 28 | 30 | 30 | 31 | |
CWIP | 0 | 0 | 0 | 6 | 9 | 10 | 12 | 2 | 2 | 0 | 0 | 1 |
Investments | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 11 | 9 |
50 | 56 | 57 | 42 | 63 | 49 | 53 | 56 | 50 | 57 | 82 | 77 | |
Total Assets | 79 | 84 | 84 | 76 | 100 | 87 | 94 | 96 | 92 | 99 | 124 | 119 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-0 | 0 | 2 | 2 | -11 | 9 | 5 | -1 | 9 | 9 | -4 | ||
-2 | -2 | -1 | -2 | -2 | -2 | -4 | -2 | 1 | -5 | -2 | ||
1 | 3 | -2 | 1 | 16 | -11 | 0 | 2 | -11 | -2 | 21 | ||
Net Cash Flow | -1 | 2 | 0 | -0 | 3 | -4 | 1 | -1 | -1 | 2 | 15 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 61 | 56 | 59 | 57 | 60 | 69 | 62 | 83 | 68 | 70 | 84 | 116 |
Inventory Days | 299 | 283 | 234 | 369 | 380 | 327 | 307 | 238 | 213 | 200 | 243 | 176 |
Days Payable | 103 | 104 | 58 | 78 | 123 | 115 | 151 | 126 | 122 | 124 | 115 | 90 |
Cash Conversion Cycle | 257 | 235 | 236 | 348 | 318 | 282 | 218 | 195 | 159 | 146 | 213 | 202 |
Working Capital Days | 75 | 93 | 93 | 124 | 251 | 142 | 94 | 128 | 58 | 44 | 85 | 186 |
ROCE % | 3% | 4% | 5% | 6% | 7% | 3% | 4% | -1% | 10% | 6% | 5% | -10% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
22h - Kerala Ayurveda's subsidiary acquired 51% stake in Singapore-based OM VEDIC HERITAGE for SGD 2.8L.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Annual Secretarial Compliance Report for FY25 with multiple regulatory non-compliances and governance issues.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 28 May
- Announcement under Regulation 30 (LODR)-Newspaper Publication 28 May
-
Disclosure Under Regulation 8(2)
27 May - Kerala Ayurveda amends Code for Fair Disclosure of Unpublished Price Sensitive Information as per SEBI regulations.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2018TranscriptNotesPPT
Business Overview:[1]
Company manufactures Ayurveda products and deals in Ayurveda Research, Academies, Clinics, Hospitals, Ayurvedic Wellness Resorts and Services, cultivation of Ayurveda herbs, and maintaining a herbarium of medicinal plants